Limfadenopati Tuberkulosis dengan Drugs-induced Hepatitis (DIH) di Sikka, Nusa Tenggara Timur, Indonesia
DOI:
https://doi.org/10.55175/cdk.v51i1.1181Kata Kunci:
Drugs-induced hepatitis, limfadenopati TB, OATAbstrak
Latar belakang: Limfadenopati TB merupakan TB ekstraparu terbanyak dengan persentase 35% total kasus di dunia. Drugs-induced hepatitis (DIH) adalah salah satu risiko efek samping obat anti-tuberkulosis (OAT). Kasus: Pria berusia 18 tahun dengan beberapa benjolan di leher sebelah kanan yang dirasa nyeri sejak 2 minggu. Pemeriksaan fisik mendapatkan beberapa benjolan submandibular dan supraklavikula kanan. Biopsi benjolan mendapatkan hasil limfadenitis granulomatous supuratif. Pasien didiagnosis limfadenopati TB dan diberi OAT Kategori 1. Lima hari kemudian, pasien mual muntah dan terjadi peningkatan AST/ALT. OAT dihentikan sementara hingga klinis dan laboratorium kembali normal. OAT selanjutnya diberikan secara individual. Simpulan: Pasien TB dan DIH memerlukan terapi individual berdasarkan toleransi terhadap obat. Perlu pemantauan klinis dan laboratorium saat pengobatan agar efek samping dapat dicegah dan pengobatan bisa berhasil.
Unduhan
Referensi
Jameson J, Kasper D, Longo D, Fauci A, Hauser S, Loscalzo J. Harrison's principles of internal medicine. 20th ed. New York: Mc Graw Hill Education; 2018.
Subuh M, Priohutomo S, Dinihari T, Siagian V, Uyainah A, Nawas A, et al. Pedoman nasional pengendalian tuberkulosis. Jakarta: Kementerian Kesehatan RI; 2014.
Kementerian Kesehatan. Peraturan Menteri Kesehatan Republik Indonesia nomor 67 Tahun 2016. Jakarta; 2016.
Menteri Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor.HK.01.07/Menkes/755/2019 tentang pedoman nasional pelayanan kedokteran tata laksana tuberkulosis. Jakarta; 2019.
Pang Y, An J, Shu W, Huo F, Chu N, Gao M, et al. Epidemiology of extrapulmonary tuberculosis among inpatients, China, 2008–2017. Emerging Infect Dis. 2019;25(3):457-64.
Wesnawa M, Kusmiati T. Drug induced hepatitis pada tuberkulosis paru dengan multisite tuberkulosis ekstraparu. J Respirasi. 2020;5(2):34.
Saukkonen J, Cohn D, Jasmer R, Schenker S, Jereb J, Nolan C, et al. An official ATS statement: Hepatotoxicity of antituberculosis therapy. Am J Respir Critical Care Med. 2006;174(8):935-52.
Sun Q, Zhang Q, Gu J, Sun W, Wang P, Bai C, et al. Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous druginduced liver injury: A prospective cohort study. Pharmacoepidemiol Drug Safety 2016;25(8):908-17.
Bulut Gökten D, Katipoglu B, Basara E, Ates I, Yılmaz N. A case report of peritoneal tuberculosis: A challenging diagnosis. Case Rep Infect Dis. 2018;2018:1-3.
Treatment of tuberculosis: Guidelines. 4th ed. WHO Press; 2020.
Latief M, Dar W, Sofi N, Dar I, Kasana B, Hussain M, et al. Novel risk factors and early detection of anti tubercular treatment induced liver injury-Looking beyond American Thoracic Society guidelines. Indian J Tuberculosis 2017;64(1):26-32.
Mohan N, Kumar J, Chakrawarty A, Ranjan P. Comprehensive review of anti-tubercular treatment induced liver injury. Internat J Basic Clin Pharmacol. 2015;4(3):397-403.
Kimura Y, Shimada M, Kawashima M, Yamane A, Nagai H, Matsui H. Relapse of cervical tuberculous lymphadenitis immediately after completion of effective antituberculosis treatments. Respirol Case Reports 2020;8(4):e00555.
Jiao Y, Chen J, Zeng X. Acute paradoxical reaction of cervical tuberculous lymphadenitis prompted by a misuse of etimicin sulphate. BMJ Case Rep. 2012;2012:bcr1220115458.
Seok H, Jeon J, Oh K, Choi H, Choi W, Lee Y, et al. Characteristics of residual lymph nodes after six months of antituberculous therapy in HIVnegative individuals with cervical tuberculous lymphadenitis. BMC Infect Dis. 2019;19(1):867.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2024 David Denada Rahmad, Asep Purnama
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
